PRV-1 and NB1 are alleles of the polymorphic gene CD177, which belongs to the Ly-6/uPAR superfamily. 1 PRV-1 was initially isolated through studies of subtractive hybridization, and an elevated neutrophil PRV-1 mRNA level was proposed as a marker for the diagnosis of polycythemia vera (PV). 2 In a study on 235 patients with Ph-negative chronic myeloproliferative disorders, we found increased neutrophil CD177 mRNA levels in PV patients, but concluded that neutrophil CD177 mRNA overexpression, rather than a specific marker of disease, is a marker of abnormal neutrophil production and/or release in PV patients. 3 Similar observations were made by other investigators. 4, 5 Recent studies suggest that evaluation of neutrophil CD177 mRNA may be employed for evaluating response to treatment. In a German study, four PV patients had a remarkable reduction in CD177 mRNA expression following treatment with interferon alpha. 6 In a recent letter, Teofili et al 7 suggest that this parameter may also be used for monitoring treatment in patients with essential thrombocythemia (ET).
With the aim of studying this issue in our cohort of 210 patients with PV and ET, we correlated CD177 expression with treatment and response status. CD177 was quantitated as reported previously. 3 Non parametric Kolmogorov-Smirnov (KS) test was used to analyze differences in CD177 mRNA expression. Diseases were classified as PV (n ¼ 99) and ET (n ¼ 111). Treatments were classified as cytotoxic (hydroxyurea and pipobroman), interferon or phlebotomy; 85 patients were out of therapy. Disease status was classified as complete response (hemoglobin o17 g/dl for males and o15 g/dl for females; platelets p400 Â 10 9 /l) or out of complete response. Median neutrophil CD177 mRNA expression values were 82.8 (range 0.6-3683) in patients under cytotoxic therapy, 36.1 (range 0.5-843) under interferon, 16.2 (range 2.8-2352.5) under phlebotomy and 28.5 (range 0-471.1) in patients out of treatment (Figure 1a ). Nonparametric analysis showed that patients receiving cytotoxic agents had a significantly higher CD177 mRNA expression than those receiving interferon (Po0.025), phlebotomy (Po0.01) and no therapy (Po0.01). No significant differences were found among patients out of treatment and patients treated with interferon or phlebotomy. According to disease status, median CD177 expressions were 41.5 (range 0.6-1616.1) in patients in complete response and 38.5 (range 0-3683) in those out of complete response (Figure 1b) , without reaching a significant difference.
These findings suggest that neutrophil CD177 mRNA expression is unlikely to be useful for monitoring response to treatment in patients with PV or ET. The reduction found in patients receiving interferon alpha might reflect a direct effect of this cytokine on gene expression rather than disease activity. On the other hand, the reason for the higher expression of CD177 mRNA in patients receiving cytotoxic therapy (hydroxyurea or pipobroman) remains unclear but might be due to altered neutrophil release. In fact, we previously found that neutrophils isolated from the bone marrow, or from peripheral blood following granulocyte colony-stimulating factor administration, show markedly higher CD177 expression than circulating granulocytes on steady state. 3 
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